# Validation of the 18 kiloDalton Translocator Protein (TSPO) as a Novel Neuroimmunodulatory Target

> **NCT03850301** · NA · RECRUITING · sponsor: **Imperial College London** · enrollment: 44 (estimated)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** XBD173
- **DRUG:** Etifoxine

## Key facts

- **NCT ID:** NCT03850301
- **Lead sponsor:** Imperial College London
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2018-01-01
- **Primary completion:** 2025-01-31
- **Final completion:** 2025-01-31
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2024-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03850301

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03850301, "Validation of the 18 kiloDalton Translocator Protein (TSPO) as a Novel Neuroimmunodulatory Target". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03850301. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*